<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE NewsML SYSTEM "http://idsdat06.reuters.com/newsml/NewsMLv1.0.dtd" [
  <!ENTITY % xhtml SYSTEM "http://idsdat06.reuters.com/newsml/xhtml1-strict.dtd">
  %xhtml;
]>
<!--src: rtr2newsml0.991-->
<NewsML Duid="MTFH96313_2002-09-23_13-00-44_L20164844_NEWSML">
    <Catalog Href="http://idsdat06.reuters.com/newsml/catalog/catalog-reuters-master_catalog_1.xml"/>
    <NewsEnvelope>
        <DateAndTime>20020923T130044+0000</DateAndTime>
        <NewsService FormalName="RTR_TNS"/>
        <NewsProduct FormalName="TXT"/>
        <Priority FormalName="3"/>
    </NewsEnvelope>
    <NewsItem Duid="MTFH96313_2002-09-23_13-00-44_L20164844_NEWSITEM">
        <Identification>
            <NewsIdentifier>
                <ProviderId>reuters.com</ProviderId>
                <DateId>20020923</DateId>
                <NewsItemId>MTFH96313_2002-09-23_13-00-44_L20164844</NewsItemId>
                <RevisionId Update="N" PreviousRevision="0">1</RevisionId>
                <PublicIdentifier>urn:newsml:reuters.com:20020923:MTFH96313_2002-09-23_13-00-44_L20164844:1</PublicIdentifier>
            </NewsIdentifier>
            <DateLabel>2002-09-23 13:00:44 GMT (Reuters)</DateLabel>
        </Identification>
        <NewsManagement>
            <NewsItemType FormalName="News"/>
            <FirstCreated>20020923T130044+0000</FirstCreated>
            <ThisRevisionCreated>20020923T130044+0000</ThisRevisionCreated>
            <Status FormalName="Usable"/>
            <Urgency FormalName="3"/>
        </NewsManagement>
        <NewsComponent EquivalentsList="no" Essential="no" Duid="MTFH96313_2002-09-23_13-00-44_L20164844_MAIN_NC" xml:lang="en">
            <TopicSet FormalName="HighImportance">  <Topic Duid="ts_1">  <TopicType FormalName="Chemicals"/>  <FormalName Scheme="N2000">CHE</FormalName>  <FormalName Scheme="IPTCSubjectCodes">04002000</FormalName>  <Description xml:lang="en">Chemicals</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_2">  <TopicType FormalName="Geography"/>  <FormalName Scheme="N2000">WEU</FormalName>  <Description xml:lang="en">Western Europe</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_3">  <TopicType FormalName="Geography"/>  <FormalName Scheme="N2000">EUROPE</FormalName>  <Description xml:lang="en">Europe</Description>  <Property FormalName="WhyPresent" Value="Ancestor"/>  </Topic>  <Topic Duid="ts_4">  <TopicType FormalName="Geography"/>  <FormalName Scheme="N2000">DE</FormalName>  <Description xml:lang="en">Germany</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_5">  <TopicType FormalName="Pharmaceuticals; Health; Personal Care"/>  <FormalName Scheme="N2000">DRU</FormalName>  <FormalName Scheme="IPTCSubjectCodes">04002006</FormalName>  <Description xml:lang="en">Pharmaceuticals (sub-industry)</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_6">  <TopicType FormalName="Geography"/>  <FormalName Scheme="N2000">US</FormalName>  <Description xml:lang="en">United States of America</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_7">  <TopicType FormalName="Geography"/>  <FormalName Scheme="N2000">GB</FormalName>  <Description xml:lang="en">United Kingdom</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_8">  <TopicType FormalName="Reuters Legacy Code"/>  <FormalName Scheme="N2000">NEWS</FormalName>  <Description xml:lang="en">General News</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  <Topic Duid="ts_9">  <TopicType FormalName="CategoryCode"/>  <FormalName Scheme="MediaCategory">OEC</FormalName>  <Description xml:lang="en">Economic news, EC, business/financial pages</Description>  <Property FormalName="WhyPresent" Value="Classifier"/>  </Topic>  </TopicSet>
            <Role FormalName="Main"/>
            <AdministrativeMetadata>
                <FileName>2002-09-23T130044Z_01_L20164844_RTRIDST_0_HEALTH-GLAXO-BAYER-VARDENAFIL.XML</FileName>
                <Provider>
                    <Party FormalName="Reuters"/>
                </Provider>
                <Source>
                    <Party FormalName="Reuters"/>
                </Source>
                <Property FormalName="SourceFeed" Value="IDS"/>
                <Property FormalName="IDSPublisher" Value="http://www.reuters.com/ids"/>
            </AdministrativeMetadata>
            <!--Single "Main Text" inner NewsComponent-->
            <NewsComponent EquivalentsList="no" Essential="no" Duid="MTFH96313_2002-09-23_13-00-44_L20164844_MAIN_TEXT_NC" xml:lang="en">
                <Role FormalName="Main Text"/>
                <NewsLines>
                    <HeadLine>Bayer, GSK claim benefits for new impotence drug</HeadLine>
                    <ByLine/>
                    <DateLine>September 23, 2002</DateLine>
                    <CreditLine>REUTERS</CreditLine>
                    <CopyrightLine>Â© Reuters 2002. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.</CopyrightLine>
                    <SlugLine>HEALTH-GLAXO-BAYER-VARDENAFIL</SlugLine>
                    <NewsLine>
                        <NewsLineType FormalName="Caption"/>
                        <NewsLineText>HEALTH-GLAXO-BAYER-VARDENAFIL:Bayer, GSK claim benefits for new impotence drug</NewsLineText>
                    </NewsLine>
                </NewsLines>
                <DescriptiveMetadata>
                    <Language FormalName="en"/>
                    <OfInterestTo FormalName="BNX"/>
                    <OfInterestTo FormalName="AFA"/>
                    <OfInterestTo FormalName="CSA"/>
                    <OfInterestTo FormalName="LBY"/>
                    <OfInterestTo FormalName="RWSA"/>
                    <OfInterestTo FormalName="RWS"/>
                    <OfInterestTo FormalName="REULB"/>
                    <OfInterestTo FormalName="GNS"/>
                    <OfInterestTo FormalName="SXNA"/>
                    <TopicOccurrence Importance="High" Topic="#ts_1"/>
                    <TopicOccurrence Importance="High" Topic="#ts_2"/>
                    <TopicOccurrence Importance="High" Topic="#ts_3"/>
                    <TopicOccurrence Importance="High" Topic="#ts_4"/>
                    <TopicOccurrence Importance="High" Topic="#ts_5"/>
                    <TopicOccurrence Importance="High" Topic="#ts_6"/>
                    <TopicOccurrence Importance="High" Topic="#ts_7"/>
                    <TopicOccurrence Importance="High" Topic="#ts_8"/>
                    <TopicOccurrence Importance="High" Topic="#ts_9"/>
                </DescriptiveMetadata>
                <ContentItem Duid="MTFH96313_2002-09-23_13-00-44_L20164844_MAIN1_TEXT_CI">
                    <MediaType FormalName="Text"/>
                    <Format FormalName="XHTML"/>
                    <Characteristics>
                        <Property FormalName="ContentID" Value="urn:newsml:reuters.com:20020923:MTFH96313_2002-09-23_13-00-44_L20164844_TXT:1"/>
                        <Property FormalName="ContentCreationDateAndTime" Value="20020923T130044+0000"/>
                        <Property FormalName="USN" Value="L20164844"/>
                        <Property FormalName="Creator" Value="RTR_JANUS 2.300"/>
                    </Characteristics>
                    <DataContent>
                        <html xmlns="http://www.w3.org/1999/xhtml">
                            <head>
                                <title/>
                            </head>
                            <body>
                                <p> LONDON, Sept 23 (Reuters) - Bayer AG and GlaxoSmithKline Plc   released promising new clinical data on Monday on their  impotence drug vardenafil, which is vying for a share of the  lucrative erectile dysfunction market.</p>
                                <p> Bayer and GSK believe they have a potential  $1-billion-a-year product in vardenafil to rival Pfizer Inc's  Viagra pill, which saw sales of more than $1.5 billion last  year.</p>
                                <p> Results presented at a medical conference in Montreal showed  vardenafil produced a consistent improvement in erectile  function over time in a three-month study involving 800 men.</p>
                                <p> On average 74 percent of patients achieved successful  penetration when taking the drug and continued to report success  in 91 percent of subsequent attempts.</p>
                                <p> A second Phase III study showed the drug helped up to 71  percent of men with erectile dysfunction resulting from prostate  cancer surgery, a traditionally difficult to treat group.</p>
                                <p> The two companies also published a survey of over 27,000 men  indicating dissatisfaction with current treatment options for  the condition.</p>
                                <p> U.S. regulators approved vardenafil in principle two months  ago, but asked for new studies that will delay its launch until  next year.</p>
                                <p> Bayer and GSK are racing against Eli Lilly &amp; Co and ICOS  Corp which have a rival product, called Cialis, at a similar  stage in development.</p>
                                <p> Analysts estimate the market for impotence drugs will rise  to between $3 billion and $4 billion by 2006 from $1.6 billion  today.    </p>
                            </body>
                        </html>
                    </DataContent>
                </ContentItem>
            </NewsComponent>
        </NewsComponent>
    </NewsItem>
</NewsML>
